Company / EPS (Diluted)
Tempest Therapeutics, Inc. EPS (Diluted) History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.70
FY2017
5-year range
-$2.70 / -$1.80
FY2015-FY2017
Trend
-23.3%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $-1.80 to $-2.70 over the past 2 years.
Based on SEC 10-K filings.
-2.70 in FY2017.
Declined from $-1.80 to $-2.70 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, eps (diluted) decreased 23.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2017 | -$2.70 | -23.3% |
| FY2016 | -$2.19 | -21.7% |
| FY2015 | -$1.80 | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026